Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252290 · ClinicalTrials.gov registry record · Phase 2
Breast Cancer Risk Biomarkers in Postmenopausal Women
A Phase 2 study, sponsored by Carol Fabian, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01252290 is a Phase 2 study that has completed, run by Carol Fabian, MD. The registered enrollment target is 35 participants.
The verdict
NCT01252290, a Phase 2 study, has completed, sponsored by Carol Fabian, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer. This drug is currently approved by the FDA for reducing blood levels of triglycerides.
Interventions
- DRUG Lovaza™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01252290
The ClinicalTrials.gov registry entry for NCT01252290 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carol Fabian, MD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lovaza™ is the first listed.
NCT01252290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01252290 about?
NCT01252290 is a clinical study titled "Breast Cancer Risk Biomarkers in Postmenopausal Women". This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer. This drug is currently approved by the FDA for reducing blood levels of triglycerides.
What is the current status of trial NCT01252290?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2010-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01252290?
The interventions under investigation include: Lovaza™ (DRUG).
Who is sponsoring clinical trial NCT01252290?
This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.